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Hereditary non-polyposis colorectal cancer (HNPCC) is caused by mutations in one of the mismatch repair genes MLH1, MSH2,
MSH6,o rPMS2 and results in high-level microsatellite instability (MSI-high) in tumours of HNPCC patients. The MSI test is
considered reliable for indicating mutations in MLH1 and MSH2, but is questioned for MSH6. Germline mutation analysis was
performed in 19 patients with an MSI-high tumour and absence of MSH2 and/or MSH6 protein as determined by
immunohistochemistry (IHC), without an MLH1 or MSH2 mutation, and in 76 out of 295 patients suspected of HNPCC, with a
non-MSI-high colorectal cancer (CRC). All 295 non-MSI-high CRCs were analysed for presence of MSH6 protein by IHC. In 10
patients with an MSI-high tumour without MSH2 and/or MSH6 expression, a pathogenic MSH6 mutation was detected, whereas no
pathogenic MSH6 mutation was detected in 76 patients with a non-MSI-high CRC and normal MSH6 protein expression. In none of
the 295 CRCs loss of MSH6 protein expression was detected. The prevalence of a germline MSH6 mutation is very low in HNPCC
suspected patients with non-MSI-high CRC. Microsatellite instability analysis in CRCs is highly sensitive to select patients for MSH6
germline mutation analysis.
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Hereditary non-polyposis colorectal cancer syndrome (HNPCC) is
an autosomal-dominant inherited disorder predisposing to colo-
rectal cancer (CRC) and several other cancers at an early age,
including endometrial carcinoma. It is clinically suspected by
Amsterdam criteria and Bethesda guidelines (Rodriguez-Bigas
et al, 1997; Umar et al, 2004). Hereditary non-polyposis colorectal
cancer is caused by mutations in one of the mismatch repair
(MMR) genes (MLH1, MSH2, MSH6, and PMS2) and is char-
acterised by tumours that show microsatellite instability (MSI).
Failure of MMR results in MSI especially in short repetitive
sequences. Molecular testing for HNPCC can be performed by
testing tumours for MSI and absence of MLH1, PMS2, MSH2 and/
or MSH6 as determined by immunohistochemistry (IHC), and
germline mutation analysis of MMR genes.
In clinical practice MSI analysis is used as a prescreening tool to
select families for further analysis of MMR gene defects. Germline
mutations in the MSH6 MMR gene account for approximately
15–30% of cases of HNPCC (Hampel et al, 2005; Barnetson et al,
2006; Niessen et al, 2006). However MSH6 mutation carriers were
reported to have tumours without an MSI-high pattern (Berends
et al, 2002; Hendriks et al, 2004; Plaschke et al, 2004), whereas in
MLH1 and MSH2 mutation carriers almost all HNPCC-associated
tumours show MSI (Lynch and Lynch, 2005). The reliability of MSI
analysis to select patients at risk for MSH6 mutations is therefore
questioned. As germline mutation analysis and IHC of MMR
proteins is almost exclusively initiated when MSI analysis shows
MSI, we might miss MSH6 germline mutations.
The aim of this study was to establish the prevalence of MSH6
mutations in HNPCC suspected patients without MSI in their
tumours to investigate the value of MSI analysis to detect MSH6
mutations.
MATERIALS AND METHODS
The study is based on 617 tumours of patients or their family
members suspected of HNPCC that visited our clinical genetics
department in which MSI and subsequent analyses were performed
between 1997 until 2006 (Figure 1). In the families analysed in our
study MSI analysis is performed in the tumour of the youngest
relative available. All findings in this group that were available at
1-1-2006 are included in this study. In 529 tumours of patients a
reliable distinction between MSI-high and MSI-stable/low could be
made using the standard set of markers (Boland et al, 1998). IHC
of MMR proteins became available and was applied for from 1999,
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sin some cases retrospectively. IHC of the MSH6 protein was
performed in all tumours regardless of MSI results. IHC of all
MMR proteins was performed in case of an MSI- high or MSI-low
tumour or when other tissue than CRC was tested, such as
endometrial cancer, gastric cancer, sebaceous carcinoma, urothe-
lial cell carcinoma, and brain tumours (Rodriguez-Bigas et al,
1997). We focused on two separate cohorts of patients; patients
with and without MSI in their tumour DNA. The pedigrees made as
a part of the genetic counselling procedure were studied for
fulfilment of Amsterdam II criteria and Bethesda guidelines
(Rodriguez-Bigas et al, 1997; Umar et al, 2004).
The study was performed according to the rules of the Medical
Ethics Committee of the Radboud University Nijmegen Medical
Centre.
Molecular analysis
For MSI analysis normal and tumour tissues were extracted from
formalin- fixed and paraffin-embedded tissues. The Bethesda
microsatellite panel D2S123, D5S346, D17S250, BAT25, and BAT26
(Boland et al, 1998) was used essentially according to methods
described previously (Hoogerbrugge et al, 2003). A tumour was
considered MSI-high when instability was found in X2 out of five
markers (n¼91) and MSI-stable or low in case of instability in p1
out of five markers (n¼438). In 178 samples the mononucleotide
marker BAT40 was included in the standard marker set. IHC of the
MMR proteins was performed with the monoclonal antibodies
against MSH6 (Transduction lab code: G70220), MLH1 (Pharmin-
gen code: 51–1327gr), PMS2 (Pharmingen code: 556415), and
MSH2 (Oncogene code: NA26). Germline MSH6 mutation analysis
of the coding regions and splice sites of the MSH6 gene was
performed with a combination of sequence analysis (exon 1, splice
acceptor site of exon 10), one-dimensional denaturing gradient gel
electrophoresis (exons 2 up to and including 10) essentially as
described by Wu et al (1999) and multiplex ligation-dependent
probe amplification (MRC Holland) for the detection of exon
deletions and duplications (exon 1 to 10). Only changes located
within 10 nucleotides of the coding region that have not been
described as polymorphisms before, are reported.
Patients with an MSI-high tumour
MSH6 germline mutation analysis was performed in a group of
19 patients with MSI-high HNPCC-associated tumours and loss of
MSH6 expression in which MLH1 and MSH2 mutations were
excluded. Nine of these tumours showed loss of MSH6 expression
in the presence of MSH2 expression and 10 showed loss of both
MSH2 and MSH6 expression, of which two were difficult to
interpret and possibly also showed loss of PMS2 expression.
Microsatellite instability patterns of HNPCC-associated tumours of
12 MLH1,2 2MSH2, and 10 MSH6 mutation carriers were studied
to compare the instability patterns of tumours of patients with
No MSH6 mutation 10 MSH6 mutations in 9 families
MSH6 mut. 0/4
MLH1/MSH2
mut. 0/5
Not tested: 3
MSH6 mut. 0/3
MLH1/MSH2
mut. 0/7
Not tested: 2
MSH6 mut. 2/10
MLH1/MSH2
mut. 0/11
Not tested: 1
MSH6 mut. 8/9
MSH6 variant 1/9
MSH6 mut. in family 1
MLH1/MSH2 mut. 0/9
Not tested: 2
No MSH6 mut.
in brother
MSH6 mut. 0/89
CRC 76
Non-CRC 13
362 present
MSH6 expr.
CRC 295
Non-CRC 67
1 loss of
MSH6 expr.
Metastasis 1
11
 loss of
MSH6 expr.
12
loss of MSH2 and
MSH6 expr.
(2 also possible
PMS2 loss)
9
loss of MLH1
and/or PMS2 expr.
9
normal expr.
(2 MSH6 not
informative)
50 other ‘non MSH6’ cause 41 MSI high 363 IHC MSH6 performed
and interpretable
438 MSI stable or low 91 MSI high
Exclusion: MSI high
tumours due to (familial)
MLH1, MSH2, PMS2
mutations (n=37) or
hypermethylation MLH1
promoter (n=13)
529 interpretable MSI analyses
Exclusion:
* Insufficient number of standard
markers are informative or
* Other cause cancer is found
(APC/MutYH) or
* MSI analysis is performed in
tumour not known to be in
HNPCC spectrum*
617 MSI analyses
after genetic counselling
Immunohistochemistry
Mutation analysis
Figure 1 Flowchart MSI analyses. *HNPCC spectrum: CRC, endometrial cancer, sebaceous carcinoma, urothelial cell carcinoma, and brain tumour. MSH6
mut: found pathogenic MSH6 mutations vs number of patients in which MSH6 was analysed; MLH1/MSH2 mut: found pathogenic MLH1/MSH2 mutations vs
number of patients in which MLH1 and MSH2 were analysed; not tested: number of patients in which no mutation analyses were performed.
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sgermline mutations in MSH6 to those with germline mutations in
MLH1 and MSH2.
Patients with a non-MSI-high tumour
Three hundred and sixty-three non-MSI-high HNPCC-associated
tumours (295 CRC) were analysed out of 335 families. Patients
most suspected of HNPCC were selected by fulfilment of at least
one of the following criteria; (1) age at diagnosis below 50 years,
(2) first degree relative with an HNPCC-related tumour, or (3)
second CRC. Of the patients that fulfilled one or more of these
criteria a subgroup of 89 patients, 76 of whom had CRC, and one
first degree relative, were analysed for MSH6 germline mutations.
Statistical analysis
Categorical variables were compared with the use of the Fisher’s
exact test using SPSS, version 12.0. A P-value of 0.05 is considered
as threshold for statistical significance.
RESULTS
MSH6 mutation analysis in patients with an MSI-high
tumour
In a group of 19 patients with both an MSI-high HNPCC-
associated tumour and loss of MSH6 expression, but no detectable
defect in MLH1 or MSH2, 10 pathogenic mutations in MSH6 were
found in nine families (Table 1). Besides the nine different MSH6
germline mutations found in patients with an MSI-high tumour,
two pathogenic mutations in MSH6 were found in patients in
whom MSI analysis could not be performed. The mean age at
diagnosis of the 11 index patients from the families with a
pathogenic MSH6 mutation was 44 years (range 36–57). The MSI
analyses in nine of these index patients with an MSH6 mutation
was performed on four endometrial, four colorectal, and one
urothelial cell cancer. All MSH6 mutation carriers fulfil one or
more Bethesda guidelines and in 64% of the families the
Amsterdam II criteria are fulfilled. In the MSH6 families
endometrial cancers occur as frequently as CRCs.
Of the remaining nine tumours with loss of MSH6 expression,
eight tumours also showed loss of MSH2 expression of which two
were difficult to interpret and possibly showed loss of PMS2
expression as well, suggesting the presence of an as yet undetected
MSH2 (or PMS2) germline mutation. One tumour, a CRC
developed at age 53, exclusively showed loss of the MSH6 protein.
In this female patient an MSH6 variant c.2117T4C (p.Phe706Ser)
was found of which the pathogenicity is uncertain. She also carries
a pathogenic mutation in BRCA2 (c.3269del (p.Met1080fs)). The
patients’ mother carries the same MSH6 variant but not the BRCA2
mutation. She was diagnosed with endometrial cancer at age 62.
Microsatellite instability analysis and IHC on her tumour were
inconclusive.
Stability in one or more of the dinucleotide markers occurred
significantly more often in colorectal tumours of MSH6 than of
MLH1 and MSH2 mutation carriers (Table 2). Stability of
Table 1 Characteristics of patients with a germline mutation in MSH6
MSI high
Tested cancer
and age at
diagnosis
Pathogenic
mutation MSH6
Instable
mono-nucleotides
Instable
di-nucleotides
IHC
MSH6
IHC
MSH2
Amsterdam
criteria II
Bethesda
A
Bethesda
B
EN in
family
CRC in
family
CO 42 c.265 ?_457+?dup 2/3 2/3 Neg Pos +   ++ +
EN 57
a c.814G4T (p.Glu272X) 3/3 0/3 Neg Pos +   ++ +
CO 52
b c.651dup (p.Lys218X) 2/2 3/3 Neg Pos + + EN 37 + + +
CO 58
b c.651dup (p.Lys218X) 3/3 2/3 Neg Neg + + CO 60 + + +
EN 36 c.3838C4T (p.Gln1280X) 2/2 1/3 Neg Pos +   ++ +
CO 50 c.3273dup (p.Lys1092X)) 2/2 2/3 Neg Pos + +CO 46/CO 50 + + +
EN 43 c.3261dup (p.Phe1088fs) 2/2 3/3 Neg Neg +   ++  
CO 39 c.3261del (p.Phe1088fs) 2/2 2/3 Neg Pos +   +   +
EN 38 c.1135_1139del (p.Arg379X) 2/2 1/3 Neg Pos   +O 38   +  
UR 56 c.1 ?_475+? del 3/3 0/3 Neg Pos   +UR 57SEB 59 +   +
EN 38 c.3678_3706dup (p.Ala1236fs) nt nt nt    ++  
CO 47 c.2815C4T (p.Gln939X) nt
c nt nt    +   +
Total 7/11 4/11 10/11 8/11 8/11
(64%) (36%) (91%) (73%) (73%)
Bethesda A: Proband with two HNPCC-related cancers, Bethesda B: Proband and first degree relative with HNPCC-related cancer, one diagnosed o50y. EN¼endometrial
cancer, CO¼colorectal cancer, UR¼urothelial cell carcinoma, SEB¼sebaceous adenoma, O¼ovarian cancer, Neg¼negative, Pos¼positive, nt¼not tested;
IHC¼immunohistochemistry; MSI¼microsatellite instability.
aThis patient also has an UV c.65G4C (p.Gly22Ala) in MLH1
bPatients from same family.
cTumour of patients
father showed MSI and no MSH6 expression.
Table 2 Results of the MSI analysis in MSH6, MLH1 and MSH2 mutation carriers
MSI pattern MSH6 mutation carriers MLH1 and MSH2 mutation carriers P-value Fisher exact
One or more of three dinucleotides
a stable
CRC 4/5 (80%) 4/22 (18%) 0.017
Non CRC 4/5 (80%) 1/6 (17%) NS
One or more mononucleotides
b stable
CRC only 1/5 (20%) 2/26 (8%) NS
Non CRC 0/5 (0%) 0/6 (0%) NS
NS¼not significant; CRC¼colorectal cancer; MSI¼microsatellite instability.
aD2S123, D5S346, and D17S250.
bBAT25 and BAT26.
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smononucleotide markers is uncommon in tumours of MSH6 as
well as MLH1 and MSH2 mutation carriers.
MSH6 mutation analysis in patients with a non-MSI-high
tumour
Immunohistochemical staining showed MSH6 expression in all
295 non-MSI-high CRCs and in 67 out of 68 other non-MSI-high
HNPCC-related tumours (Table 3).
A subgroup of patients with the highest suspicion of HNPCC,
was tested for the presence of MSH6 germline mutations. In none
of the 76 patients with CRC, or in the 13 patients with other
HNPCC-related tumours a pathogenic germline mutation in MSH6
was detected. One non-MSI-high tumour of metastatic tumour
tissue (most probably derived from a CRC) of a deceased patient
showed loss of MSH6 expression, in presence of MLH1 and MSH2
expression. Because mutation analysis could not be performed in
the deceased patient, mutation analysis in her brother was
performed. No mutation in MSH6 was detected (Table 4).
Silent variants c.3852G4A, c.2154C4T, c.1068T4C, and
c.3246G4T were found. None of these are predicted to affect
splicing and thus do not seem to have functional consequences.
The missense variant c.3101G4C (p.Arg1034Pro) that was found
in a female patient with CRC at age 43 might be pathogenic. As the
carcinoma was not available the MSI and IHC analyses were
performed in an adenoma, which might have decreased the
sensitivity of the analyses. Segregation analysis in the family
showed that her brother who had a glioma, and the mother who
had two sisters with anamnestic endometrial cancer did not carry
the MSH6 variant, making the pathogenecity of this variant less
likely.
DISCUSSION
In this study, not one pathogenic germline MSH6 mutation was
detected in HNPCC suspected patients with a non-MSI-high CRC
or HNPCC-related tumour.
Previous studies suggested that the sensitivity of MSI analysis to
predict an MSH6 mutation is low and that MSI should not be used
as a selection criterion for MSH6 mutation analysis (Wu et al,
1999), finding microsatellite stable or low patterns in 17% up to
50% (Berends et al, 2002; Hendriks et al, 2004; Plaschke et al,
2004; Niessen et al, 2006; Pinto et al, 2006) of HNPCC-associated
tumours of MSH6 mutation carriers. However careful considera-
tion of previous studies is required as part of the conclusions are
based on MSH6 missense mutations of unknown pathogenecity or
testing a sporadic tumour within an HNPCC family (a phenocopy)
as suggested by positive immunostaining of MSH6 in the tumour.
These have an unfavourable effect on the sensitivity of MSI
analysis. In addition MSI analysis on endometrial cancer, the most
frequent tumour in female MSH6 mutation carriers might decrease
its sensitivity, as it is known that the instability in these tumours is
generally less pronounced (Wijnen et al, 1999; Hendriks et al,
2004).
MSH6 mutations result in a weaker mutator phenotype
(Kolodner et al, 1999), which may be explained by the major
function of MSH6 to correct base–base mismatches and single
nucleotide deletion loops but not larger deletion loops (Parc et al,
2000). Like in previous studies (Kolodner et al, 1999; Verma et al,
1999; Parc et al, 2000) our study shows that mononucleotide
markers but not dinucleotide markers are sensitive to show
instability in tumours of MSH6 mutation carriers. The sensitivity
of MSI analysis therefore depends on the microsatellite markers
used. Enlarging the standard (Bethesda) marker set (Boland et al,
1998) with a mononucleotide marker (like BAT40) will increase the
sensitivity of MSI analysis by minimising the chance of missing
tumours with MSH6 inactivation. As data on MSI analysis of other
non-colorectal HNPCC-related tumours with defective MMR are
insufficient, we recommend additional IHC of MLH1, PMS2,
MSH2, and MSH6 proteins when MSI analysis is performed on
non-colorectal HNPCC-related cancers. Immunohistochemical
staining of MMR proteins will also improve the interpretation of
MSI patterns when a low percentage of tumour cells or an
adenoma is tested or when only one mononucleotide marker
shows instability (MSI low). When a patient is excluded from
further HNPCC analysis based on a non-MSI-high pattern in
Table 3 Overview of microsatellite stable/low tumours
Patient with
non-MSI-high
tumour and loss
of MSH6
expression
Patients with
non-MSI-high
tumours and
positive MSH6
expression
Selected group
of patients with
non-MSI-high
tumours and
positive MSH6
expression
without a
pathogenic
mutation in
MSH6
Colorectal ca 295 76
Age o50 yr 171 (58%) 62 (82%)
Other HNPCC-
related neoplasia
16 7 1 3
Endometrial ca 15 3
Gastric ca 3
Sebaceous ca 4
Urothelial cell ca 1
Brain tumour 1
Metastatic tissue 1
a 7
Small bowel 1
Adenoma
Colon 34 10
Duodenum 1
Age o50 yr 0 34 (51%) 9 (69%)
MSI¼microsatellite instability; HNPCC¼hereditary non-polyposis colorectal cancer;
ca¼cancer.
aMutation analysis in the patients’ brother showed no MSH6 mutation.
Table 4 MSI-test result and IHC protein expression pattern of tumours from patients tested for the presence of a MSH6 germline mutation
MSI MSI high MSI stable/low
IHC MSH6  MSH6  MSH6 
a MSH6  MSH6+
MSH2+ MSH2- MSH2 
a
MLH1+ MLH1+ MLH1+
a
PMS2+ PMS2+ PMS2 
a
No pathogenic mutation in MSH6 1
b 621
c 89
Pathogenic mutation in MSH6 8 2
IHC¼immunohistochemistry; MSI¼microsatellite instability.
aIHC difficult to interpret.
bWith MSH6 variant c.2117T4C (p.Phe706Ser).
cMutation analysis was performed in the
patients’ brother.
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stumour DNA, a second MSI analysis in the family should always be
considered to avoid missing a germline mutation because of an
initial test in a phenocopy.
From previous studies we know, that in MSH6 mutation carriers
CRC occurs at older age than in MLH1 and MSH2 mutation
carriers (Hendriks et al, 2004). In our study, the patients with
MSI-stable/low tumours that were analysed for MSH6 mutations
were mainly diagnosed before the age of 50. This selection is not
expected to have a large influence, because MSI analysis in the
families in our study is performed in the tumour of the youngest
relative available. The mean age of diagnosis in MSH6 mutation
carriers is above 50, but the occurrence of one relative below 50 is
expected to be present in most of the MSH6 families. The pedigrees
of the diagnosed MSH6 families in our study all contained an
affected relative diagnosed below 50 years of age.
The prevalence of MSH6 mutation carriers in HNPCC suspected
CRC patients is low, as is demonstrated by the fact that we detected
an MSH6 mutation in only about 1% of these patients. All these
mutations were found in patients with an MSI-high tumour. Data
from previous studies (Berends et al, 2002; Hendriks et al, 2004;
Plaschke et al, 2004; Barnetson et al, 2006; Niessen et al, 2006)
show that approximately 15% of colorectal tumours of MSH6
mutation carriers do not have an MSI-high pattern, whereas they
do show loss of MSH6 expression and thus might be the result of
the MSH6 germline mutation. On the other hand, approximately
5% of colorectal tumours of MSH6 mutation carriers do show
neither an MSI-high pattern nor loss of MSH6 expression and thus
might have arisen independent from the genetic background of the
carrier. Based on our finding of the low incidence of MSH6
mutations in HNPCC-suspected CRC patients and the percentage
of non-MSI-high tumours in MSH6 mutation carriers from the
literature, the probability of missing a mutation by not performing
mutation analyses in patients with non-MSI-high CRCs is expected
to be extremely low. This is confirmed by the fact that we did not
find any non-MSI-high CRC with loss of MSH6 expression, nor a
germline MSH6 mutation in any of the patients with a non-MSI-
high tumour. Our findings show that MSI analysis is highly suited
to trace CRC of carriers of MSH6 germline mutations.
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